Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

In this article, we will discuss the 10 Stocks Under $10 that Will Triple.

Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

UniSuper Management Pty Ltd turned up the financial charm, upping its Regeneron stake by 38% in Q4. The fund now owns 7,306 ...

Sei Investments Co. trimmed its Regeneron Pharmaceuticals stake by 11.3% in Q4, selling 3,371 shares and ending with 26,432.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other most profitable biotech stocks to buy right now. With improved market ...

Q4 results today: According to market experts, the banking sector is predicted to outperform market estimates, while other segments may face pressure from increased provisioning due to concerns ...

In that sense, Gilead (GILD) with lenacapavir and Regeneron (REGN) with Eylea label expansion and new formulation “theoretically have the most risk,” followed by Merck (MRK) with subcutaneous ...

We recently compiled a list of the 10 Best EV Stocks to Buy Under $50. In this article, we are going to take a look at where ...